Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plasma angiotensin-converting enzyme 2 (ACE2) is a marker for renal outcome of diabetic kidney disease (DKD) (U-CARE study 3).
Ueno A, Onishi Y, Mise K, Yamaguchi S, Kanno A, Nojima I, Higuchi C, Uchida HA, Shikata K, Miyamoto S, Nakatsuka A, Eguchi J, Hida K, Katayama A, Watanabe M, Nakato T, Tone A, Teshigawara S, Matsuoka T, Kamei S, Murakami K, Shimizu I, Miyashita K, Ando S, Nunoue T, Wada J. Ueno A, et al. Among authors: miyamoto s. BMJ Open Diabetes Res Care. 2024 May 30;12(3):e004237. doi: 10.1136/bmjdrc-2024-004237. BMJ Open Diabetes Res Care. 2024. PMID: 38816205 Free PMC article.
Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients.
Yoshikawa R, Wada J, Seiki K, Matsuoka T, Miyamoto S, Takahashi K, Ota S, Taniai K, Hida K, Yamakado M, Shikata K, Uehara Y, Urade Y, Makino H. Yoshikawa R, et al. Among authors: miyamoto s. Diabetes Res Clin Pract. 2007 Jun;76(3):358-67. doi: 10.1016/j.diabres.2006.09.004. Epub 2006 Sep 27. Diabetes Res Clin Pract. 2007. PMID: 17007955
Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophage: anti-inflammatory effect of cholecystokinin.
Miyamoto S, Shikata K, Miyasaka K, Okada S, Sasaki M, Kodera R, Hirota D, Kajitani N, Takatsuka T, Kataoka HU, Nishishita S, Sato C, Funakoshi A, Nishimori H, Uchida HA, Ogawa D, Makino H. Miyamoto S, et al. Diabetes. 2012 Apr;61(4):897-907. doi: 10.2337/db11-0402. Epub 2012 Feb 22. Diabetes. 2012. PMID: 22357963 Free PMC article.
Prevalence of albuminuria and renal dysfunction, and related clinical factors in Japanese patients with diabetes: The Japan Diabetes Complication and its Prevention prospective study 5.
Shikata K, Kodera R, Utsunomiya K, Koya D, Nishimura R, Miyamoto S, Tajima N; JDCP study group. Shikata K, et al. Among authors: miyamoto s. J Diabetes Investig. 2020 Mar;11(2):325-332. doi: 10.1111/jdi.13116. Epub 2019 Sep 25. J Diabetes Investig. 2020. PMID: 31317670 Free PMC article.
The hypoglycemia-prevention effect of sensor-augmented pump therapy with predictive low glucose management in Japanese patients with type 1 diabetes mellitus: a short-term study.
Katayama A, Tone A, Watanabe M, Teshigawara S, Miyamoto S, Eguchi J, Nakatsuka A, Shikata K, Wada J. Katayama A, et al. Among authors: miyamoto s. Diabetol Int. 2019 Sep 16;11(2):97-104. doi: 10.1007/s13340-019-00408-7. eCollection 2020 Apr. Diabetol Int. 2019. PMID: 32206479 Free PMC article.
Randomized trial of an intensified, multifactorial intervention in patients with advanced-stage diabetic kidney disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan).
Shikata K, Haneda M, Ninomiya T, Koya D, Suzuki Y, Suzuki D, Ishida H, Akai H, Tomino Y, Uzu T, Nishimura M, Maeda S, Ogawa D, Miyamoto S, Makino H; Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan) collaborative group. Shikata K, et al. Among authors: miyamoto s. J Diabetes Investig. 2021 Feb;12(2):207-216. doi: 10.1111/jdi.13339. Epub 2020 Aug 8. J Diabetes Investig. 2021. PMID: 32597548 Free PMC article. Clinical Trial.
3,368 results